Compare Cytokinetics Inc (CYTK) vs DigitalOcean Holdings Inc (DOCN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs DigitalOcean Holdings Inc — how do they compare? Cytokinetics Inc trades at $81.99 (market cap $11.12B), while DigitalOcean Holdings Inc trades at $123.24 (market cap $13.18B). The key difference: DigitalOcean Holdings Inc is the larger of the two by market cap, and Cytokinetics Inc is trading nearer its 52-week high, DigitalOcean Holdings Inc nearer its low. Which is the better fit depends on your goals.
| CYTK | DOCN | |
|---|---|---|
Market Cap | $11.12B | $13.18B |
Sector | Technology | Technology |
52-Week High | $87.26 | $181.29 |
52-Week Low | $33.23 | $25.74 |
Enterprise Value | $11.59B | $13.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
DigitalOcean (DOCN) trades at $123.32, down 5.49% today, with bearish technical signals but strong fundamental performance. The company reported record Q2 2026 results with revenue exceeding expectations and significant AI-driven growth. Analyst consensus remains bullish with a $174.80 price target, though technical indicators show selling pressure near-term.
The outlook remains positive given strong AI adoption and enterprise wins, with 63% analyst buy ratings supporting upside potential. Key risks include high valuation multiples and competitive cloud market pressures. The stock's current weakness presents a potential entry point for growth investors seeking AI infrastructure exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About DigitalOcean Holdings Inc
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and other countries.
Read more on DOCN →
